Advertisement


Related Videos

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement



Jul
30
Today In Oncology
Frailty and Neurocognitive Decline Among Young Adult Childhood Cancer Survivors
Association of Baseline Fatigue With Survival and Adverse Events in Patients With Advanced Cancer
Study Explores Rates of Reconstruction for Women With Inflammatory Breast Cancer Undergoing Mastectomy
Clinical Trial Results Show an Increased Risk of Death Associated With Melphalan Flufenamide
Perioperative or Postoperative Oxaliplatin/S-1 vs Postoperative Oxaliplatin/Capecitabine for Locally Advanced Gastric Cancer
View More 
Advertisement
© 2021 HSP News Service, L.L.C.
Designed by Harborside